SC
ALXN

Steph & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Steph & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-887
Closed -$139K – 243
2020
Q4 		$139K Hold
887
– – 0.11% 119
2020
Q3 		$101K Hold
887
– – 0.09% 123
2020
Q2 		$100K Buy
887
+304
+52% +$32.3K 0.1% 120
2020
Q1 		$52K Sell
583
-219
-27% -$21.5K 0.06% 142
2019
Q4 		$87K Buy
+802
New +$85.8K 0.07% 146

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steph & Co's ALXN Position: Q1 2021 in Review

Steph & Co sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 887 shares — an estimated $139K sold.

Steph & Co first reported a position in ALXN in Q4 2019 and held it in 5 quarters. The position peaked at $139K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Steph & Co reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Steph & Co sold 887 Alexion Pharmaceuticals shares in Q1 2021, an estimated $139K.
  • Steph & Co first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Steph & Co's Alexion Pharmaceuticals position peaked at $139K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Steph & Co's 13F filing for Q1 2021, filed 16 Apr 2021.